Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services

Core Insights - Palvella Therapeutics has appointed Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services to enhance payer engagement and patient support for its QTORIN™ programs targeting serious, rare skin diseases and vascular malformations [1][2][3] Company Overview - Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious, rare skin diseases and vascular malformations, with no FDA-approved therapies currently available for these conditions [5][6] - The company is developing a pipeline of product candidates based on its patented QTORIN™ platform, with a lead product candidate, QTORIN™ rapamycin, aimed at treating microcystic lymphatic malformations [6][7] Leadership and Experience - Jennifer McDonough has over 25 years of experience in the biopharmaceutical industry, particularly in rare disease access strategy and patient support, having previously contributed to the successful launch of VYJUVEK® at Krystal Biotech, which achieved $389 million in annual sales by 2025 [2][3] - McDonough's prior roles include senior leadership positions at Strongbridge Biopharma and Cencora, focusing on market access, patient services, and specialty distribution [3] Strategic Focus - The company is preparing for a potential near-term U.S. launch of QTORIN™ rapamycin, emphasizing the importance of building strong market access and patient services capabilities [2][4] - Palvella aims to support patients, caregivers, and providers from the outset of its planned U.S. launch, leveraging McDonough's expertise to establish a robust commercial infrastructure [2][4]